Review



sk4 expression  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs sk4 expression
    BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT <t>SK4</t> currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.
    Sk4 Expression, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk4 expression/product/Alomone Labs
    Average 93 stars, based on 24 article reviews
    sk4 expression - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction"

    Article Title: The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction

    Journal: PNAS Nexus

    doi: 10.1093/pnasnexus/pgae192

    BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT SK4 currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.
    Figure Legend Snippet: BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT SK4 currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.

    Techniques Used: In Vitro, Inhibition, Expressing

    Effect of BA6b9 on SK4 expression in the left atrium of rats with MI-induced HF. A) Statistical summary of overall left-atrial SK4 expression; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 14.27, Sidak's multiple comparisons test P = 0.0003). B1) Representative histological LA cross-section from a control rat (upper left), stained with DAB. B2, B3) Representative DAB-stained histological cross-sections of the LA from post-MI rats treated with vehicle (upper right) or BA6b9 (lower left) for 21 days. Brown staining intensity indicates the level of SK4 expression in the tissue, with darker brown indicating stronger expression. B4) Negative control SK4 staining. An inset in each photograph shows the full LA tissue in low resolution.
    Figure Legend Snippet: Effect of BA6b9 on SK4 expression in the left atrium of rats with MI-induced HF. A) Statistical summary of overall left-atrial SK4 expression; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 14.27, Sidak's multiple comparisons test P = 0.0003). B1) Representative histological LA cross-section from a control rat (upper left), stained with DAB. B2, B3) Representative DAB-stained histological cross-sections of the LA from post-MI rats treated with vehicle (upper right) or BA6b9 (lower left) for 21 days. Brown staining intensity indicates the level of SK4 expression in the tissue, with darker brown indicating stronger expression. B4) Negative control SK4 staining. An inset in each photograph shows the full LA tissue in low resolution.

    Techniques Used: Expressing, Control, Staining, Negative Control

    Effect of BA6b9 on collagen deposition, α-SMA expression, and SK4 expression in the LA epicardium of rats with MI-induced HF. A) Statistical summary of LA epicardial fibrosis (analysis of six randomized epicardial fields for each atrial section, total of 18 atrial-epicardium fields per animal); vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). A1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (left upper row). The analyzed area is marked by dashed lines. A2, A3) Representative histological cross-sections of the LA from post-MI rats treated with vehicle (left middle row) or BA6b9 (left lower row) for 21 days. Sections A1–A3 were stained with Masson's Trichrome. B) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). B1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (middle upper row). B2, B3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (center) vs. BA6b9 (middle lower row) for 21 days. Sections B1–B3 were stained with Sirius Red. C) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 10.21, Sidak's multiple comparisons test P = 0.0014). C1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (right upper row). C2, C3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (right middle row) or BA6b9 (right lower row) for 21 days. Sections C1–C3 were stained with DAB. Note the marked thickening of the atrial epicardium in MI rats compared to controls as well as the significant reductions in collagen deposition (A, A1–A3), α-SMA expression (B, B1–B3), and SK4 expression (C, C1–C3) in the BA6b9-treated rats compared to the vehicle group. An inset in each photograph shows the full LA tissue in low resolution.
    Figure Legend Snippet: Effect of BA6b9 on collagen deposition, α-SMA expression, and SK4 expression in the LA epicardium of rats with MI-induced HF. A) Statistical summary of LA epicardial fibrosis (analysis of six randomized epicardial fields for each atrial section, total of 18 atrial-epicardium fields per animal); vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). A1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (left upper row). The analyzed area is marked by dashed lines. A2, A3) Representative histological cross-sections of the LA from post-MI rats treated with vehicle (left middle row) or BA6b9 (left lower row) for 21 days. Sections A1–A3 were stained with Masson's Trichrome. B) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). B1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (middle upper row). B2, B3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (center) vs. BA6b9 (middle lower row) for 21 days. Sections B1–B3 were stained with Sirius Red. C) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 10.21, Sidak's multiple comparisons test P = 0.0014). C1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (right upper row). C2, C3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (right middle row) or BA6b9 (right lower row) for 21 days. Sections C1–C3 were stained with DAB. Note the marked thickening of the atrial epicardium in MI rats compared to controls as well as the significant reductions in collagen deposition (A, A1–A3), α-SMA expression (B, B1–B3), and SK4 expression (C, C1–C3) in the BA6b9-treated rats compared to the vehicle group. An inset in each photograph shows the full LA tissue in low resolution.

    Techniques Used: Expressing, Control, Staining



    Similar Products

    93
    Alomone Labs sk4 expression
    BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT <t>SK4</t> currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.
    Sk4 Expression, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk4 expression/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    sk4 expression - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT SK4 currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.

    Journal: PNAS Nexus

    Article Title: The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction

    doi: 10.1093/pnasnexus/pgae192

    Figure Lengend Snippet: BA6b9 treatment reduces the AF substrate of post-MI rats. A) Confirmatory in vitro recordings. Left: Representative trace of WT SK4 currents in the absence and presence of 20 µM BA6b9, displaying a degree of inhibition of ≈56%. Right: Representative traces of an inside-out macropatch from a CHO cell expressing WT SK4 channels in the absence and presence of 10 µM BA6b9 under internal saturating calcium concentrations. Currents were recorded by 10 repetitive 1 s duration voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. B) BA6b9 treatment significantly reduced AF induction and AF duration. C) Example of postburst AF episodes in the vehicle (left) and BA6b9 (right) groups. D) Mean power spectrum of the AF episodes following long-term BA6b9 vs. vehicle treatment. Notably, the vehicle group demonstrated greater amplitudes over a wide range of frequencies relative to the BA6b9 group. Notch (arrow) indicates the zone where a notch filter was applied due to power supply-related noise (50 Hz). E) Quantitative analysis of delta between the power spectrum integrals of arrhythmic episodes and preburst NSR. Note the significantly higher values in the vehicle group compared to the AF events among BA6b9-treated rats.

    Article Snippet: Antigen retrieval was performed using BOND Epitope Retrieval Solution 1 (Citrate buffer, prediluted, pH 6.0) for 20 min at 100°C, followed by peroxide treatment for 10 min. For membranal staining, we primarily incubated the sections with WGA (29022, CF488 WGA, Biotium, 1:500 in PBS) conjugated with Alexa Fluor 488 for 30 min, followed by incubation with blocking buffer (10% normal goat serum, 0.1% Triton, and 10% bovine serum albumin) for 30 min. For analyses of SK4 expression and localization, we incubated the specimens with the primary antibody (ALM-051, Alomone Labs, mouse monoclonal antibody against the 3rd extracellular loop of human SK4, 1:50) for 90 min and then stained with a Cy3-conjugated secondary antibody (711-165-151, Jackson Immunoresearch Laboratories, Cy TM 3-conjugated AffiniPure Donkey Anti-Mouse, 1:100) for 90 min. For Cx43 expression and localization analyses, we incubated the specimens with the primary antibody (C6219, Sigma-Aldrich, rabbit polyclonal antibody against the C-terminus of human/rat Cx43, 1:400) for 90 min and stained with a Cy5-conjugated secondary antibody (711-175-152, Jackson Immunoresearch Laboratories, Cy TM 5-conjugated AffiniPure Donkey Anti-Rabbit, 1:200) for 90 min. At the end of the staining, we incubated the specimens with Vector TrueVIEW Autofluorescence Quenching kit (SP-8400-15, Vector laboratories) for 10 min to improve the signal-to-noise ratio and reduce autofluorescence.

    Techniques: In Vitro, Inhibition, Expressing

    Effect of BA6b9 on SK4 expression in the left atrium of rats with MI-induced HF. A) Statistical summary of overall left-atrial SK4 expression; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 14.27, Sidak's multiple comparisons test P = 0.0003). B1) Representative histological LA cross-section from a control rat (upper left), stained with DAB. B2, B3) Representative DAB-stained histological cross-sections of the LA from post-MI rats treated with vehicle (upper right) or BA6b9 (lower left) for 21 days. Brown staining intensity indicates the level of SK4 expression in the tissue, with darker brown indicating stronger expression. B4) Negative control SK4 staining. An inset in each photograph shows the full LA tissue in low resolution.

    Journal: PNAS Nexus

    Article Title: The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction

    doi: 10.1093/pnasnexus/pgae192

    Figure Lengend Snippet: Effect of BA6b9 on SK4 expression in the left atrium of rats with MI-induced HF. A) Statistical summary of overall left-atrial SK4 expression; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 14.27, Sidak's multiple comparisons test P = 0.0003). B1) Representative histological LA cross-section from a control rat (upper left), stained with DAB. B2, B3) Representative DAB-stained histological cross-sections of the LA from post-MI rats treated with vehicle (upper right) or BA6b9 (lower left) for 21 days. Brown staining intensity indicates the level of SK4 expression in the tissue, with darker brown indicating stronger expression. B4) Negative control SK4 staining. An inset in each photograph shows the full LA tissue in low resolution.

    Article Snippet: Antigen retrieval was performed using BOND Epitope Retrieval Solution 1 (Citrate buffer, prediluted, pH 6.0) for 20 min at 100°C, followed by peroxide treatment for 10 min. For membranal staining, we primarily incubated the sections with WGA (29022, CF488 WGA, Biotium, 1:500 in PBS) conjugated with Alexa Fluor 488 for 30 min, followed by incubation with blocking buffer (10% normal goat serum, 0.1% Triton, and 10% bovine serum albumin) for 30 min. For analyses of SK4 expression and localization, we incubated the specimens with the primary antibody (ALM-051, Alomone Labs, mouse monoclonal antibody against the 3rd extracellular loop of human SK4, 1:50) for 90 min and then stained with a Cy3-conjugated secondary antibody (711-165-151, Jackson Immunoresearch Laboratories, Cy TM 3-conjugated AffiniPure Donkey Anti-Mouse, 1:100) for 90 min. For Cx43 expression and localization analyses, we incubated the specimens with the primary antibody (C6219, Sigma-Aldrich, rabbit polyclonal antibody against the C-terminus of human/rat Cx43, 1:400) for 90 min and stained with a Cy5-conjugated secondary antibody (711-175-152, Jackson Immunoresearch Laboratories, Cy TM 5-conjugated AffiniPure Donkey Anti-Rabbit, 1:200) for 90 min. At the end of the staining, we incubated the specimens with Vector TrueVIEW Autofluorescence Quenching kit (SP-8400-15, Vector laboratories) for 10 min to improve the signal-to-noise ratio and reduce autofluorescence.

    Techniques: Expressing, Control, Staining, Negative Control

    Effect of BA6b9 on collagen deposition, α-SMA expression, and SK4 expression in the LA epicardium of rats with MI-induced HF. A) Statistical summary of LA epicardial fibrosis (analysis of six randomized epicardial fields for each atrial section, total of 18 atrial-epicardium fields per animal); vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). A1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (left upper row). The analyzed area is marked by dashed lines. A2, A3) Representative histological cross-sections of the LA from post-MI rats treated with vehicle (left middle row) or BA6b9 (left lower row) for 21 days. Sections A1–A3 were stained with Masson's Trichrome. B) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). B1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (middle upper row). B2, B3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (center) vs. BA6b9 (middle lower row) for 21 days. Sections B1–B3 were stained with Sirius Red. C) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 10.21, Sidak's multiple comparisons test P = 0.0014). C1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (right upper row). C2, C3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (right middle row) or BA6b9 (right lower row) for 21 days. Sections C1–C3 were stained with DAB. Note the marked thickening of the atrial epicardium in MI rats compared to controls as well as the significant reductions in collagen deposition (A, A1–A3), α-SMA expression (B, B1–B3), and SK4 expression (C, C1–C3) in the BA6b9-treated rats compared to the vehicle group. An inset in each photograph shows the full LA tissue in low resolution.

    Journal: PNAS Nexus

    Article Title: The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction

    doi: 10.1093/pnasnexus/pgae192

    Figure Lengend Snippet: Effect of BA6b9 on collagen deposition, α-SMA expression, and SK4 expression in the LA epicardium of rats with MI-induced HF. A) Statistical summary of LA epicardial fibrosis (analysis of six randomized epicardial fields for each atrial section, total of 18 atrial-epicardium fields per animal); vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). A1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (left upper row). The analyzed area is marked by dashed lines. A2, A3) Representative histological cross-sections of the LA from post-MI rats treated with vehicle (left middle row) or BA6b9 (left lower row) for 21 days. Sections A1–A3 were stained with Masson's Trichrome. B) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 16.53, Sidak's multiple comparisons test P = 0.0001). B1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (middle upper row). B2, B3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (center) vs. BA6b9 (middle lower row) for 21 days. Sections B1–B3 were stained with Sirius Red. C) Statistical summary of LA epicardial α-SMA expression; (analysis: same as in A; vehicle- vs. BA6b9-treated rats, compared to control ( n = 7, n = 8, n = 4, respectively; one-way ANOVA, F(2, 16) = 10.21, Sidak's multiple comparisons test P = 0.0014). C1) Representative histological cross-section of LA myocardium attached to the epicardial tissue from a control rat (right upper row). C2, C3) Representative histological cross-sections of the LA in post-MI rats treated with vehicle (right middle row) or BA6b9 (right lower row) for 21 days. Sections C1–C3 were stained with DAB. Note the marked thickening of the atrial epicardium in MI rats compared to controls as well as the significant reductions in collagen deposition (A, A1–A3), α-SMA expression (B, B1–B3), and SK4 expression (C, C1–C3) in the BA6b9-treated rats compared to the vehicle group. An inset in each photograph shows the full LA tissue in low resolution.

    Article Snippet: Antigen retrieval was performed using BOND Epitope Retrieval Solution 1 (Citrate buffer, prediluted, pH 6.0) for 20 min at 100°C, followed by peroxide treatment for 10 min. For membranal staining, we primarily incubated the sections with WGA (29022, CF488 WGA, Biotium, 1:500 in PBS) conjugated with Alexa Fluor 488 for 30 min, followed by incubation with blocking buffer (10% normal goat serum, 0.1% Triton, and 10% bovine serum albumin) for 30 min. For analyses of SK4 expression and localization, we incubated the specimens with the primary antibody (ALM-051, Alomone Labs, mouse monoclonal antibody against the 3rd extracellular loop of human SK4, 1:50) for 90 min and then stained with a Cy3-conjugated secondary antibody (711-165-151, Jackson Immunoresearch Laboratories, Cy TM 3-conjugated AffiniPure Donkey Anti-Mouse, 1:100) for 90 min. For Cx43 expression and localization analyses, we incubated the specimens with the primary antibody (C6219, Sigma-Aldrich, rabbit polyclonal antibody against the C-terminus of human/rat Cx43, 1:400) for 90 min and stained with a Cy5-conjugated secondary antibody (711-175-152, Jackson Immunoresearch Laboratories, Cy TM 5-conjugated AffiniPure Donkey Anti-Rabbit, 1:200) for 90 min. At the end of the staining, we incubated the specimens with Vector TrueVIEW Autofluorescence Quenching kit (SP-8400-15, Vector laboratories) for 10 min to improve the signal-to-noise ratio and reduce autofluorescence.

    Techniques: Expressing, Control, Staining